TY - JOUR
T1 - Polypoidal Choroidal Vasculopathy
AU - Goldhardt, Raquel
AU - Rosen, Bradley Simon
N1 - Funding Information:
Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S, NIH Center Core Grant P30EY014801 and Research to Prevent Blindness Unrestricted Grant.
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/3/15
Y1 - 2019/3/15
N2 - Purpose of Review: The aim of this review is to summarize developments in the treatment of active polypoidal choroidal vasculopathy (PCV). PCV is associated with a poor visual prognosis as a consequence of the condition’s hallmark polypoidal dilatation and a branching network resulting in recurrent hemorrhages and serous leakage. Recent Findings: Recent research has provided new insights into the pathogenesis of PCV. While still considered a subtype of age-related macular degeneration, suggestions that PCV belongs to a spectrum of conditions that present with a pachychoroid are increasingly well accepted. Treatment remains challenging. Combination therapy (photodynamic therapy (PDT) and intravitreal anti-vascular endothelial growth factor (VEGF)) is associated with higher polyp closure rate, but polyp closure rate has not been correlated with superior visual outcomes. Current data points to non-inferiority of anti-VEGF alone versus combined with PDT when final vision acuity is the study outcome. Summary: PCV remains a clinical challenge. Classification and treatment of the condition continue to evolve. Combination therapy may not be superior to anti-VEGF treatment alone in terms of visual acuity outcome; however, data on long-term recurrence should be compared in formulating preferred treatment plans.
AB - Purpose of Review: The aim of this review is to summarize developments in the treatment of active polypoidal choroidal vasculopathy (PCV). PCV is associated with a poor visual prognosis as a consequence of the condition’s hallmark polypoidal dilatation and a branching network resulting in recurrent hemorrhages and serous leakage. Recent Findings: Recent research has provided new insights into the pathogenesis of PCV. While still considered a subtype of age-related macular degeneration, suggestions that PCV belongs to a spectrum of conditions that present with a pachychoroid are increasingly well accepted. Treatment remains challenging. Combination therapy (photodynamic therapy (PDT) and intravitreal anti-vascular endothelial growth factor (VEGF)) is associated with higher polyp closure rate, but polyp closure rate has not been correlated with superior visual outcomes. Current data points to non-inferiority of anti-VEGF alone versus combined with PDT when final vision acuity is the study outcome. Summary: PCV remains a clinical challenge. Classification and treatment of the condition continue to evolve. Combination therapy may not be superior to anti-VEGF treatment alone in terms of visual acuity outcome; however, data on long-term recurrence should be compared in formulating preferred treatment plans.
KW - Branching vascular network
KW - Polypoidal choroidal vasculopathy
KW - Retinal detachment
KW - Serosanguinous retinal pigment epithelium detachment
KW - Vitreous hemorrhage
UR - http://www.scopus.com/inward/record.url?scp=85081089720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081089720&partnerID=8YFLogxK
U2 - 10.1007/s40135-019-00201-4
DO - 10.1007/s40135-019-00201-4
M3 - Review article
AN - SCOPUS:85081089720
VL - 7
SP - 66
EP - 72
JO - Current Ophthalmology Reports
JF - Current Ophthalmology Reports
SN - 2167-4868
IS - 1
ER -